Through Brightline Diagnostics (hyperlink), Chelsea offer a bespoke diagnostic test development service for the detection of waterborne pathogens and invasive species.
In 2020, we entered a joint venture with life sciences company StreamBio to launch Brightline DX. Combining our fluorescence imaging technology with novel fluorescent bioimaging probes (CPNs) to create the next generation of lateral flow technology, together we have developed a unique platform, Claritas, that can be applied to a wide range of targets. The existing platform allows us to offer a cost-effective service to develop diagnostic tests with high sensitivity and specificity.
Chelsea has a rich history of design and manufacture for life sciences and environmental applications. The Brightline team of highly experienced scientists and engineers will guide you through our bespoke process to ensure we truly understand your needs and develop a test that will fit your requirements.